Cargando…
Therapeutically-induced stable disease in oncology early clinical trials
RATIONALE: The RECIST guideline defines four categories of response to treatment for cancer patients according to post-baseline changes in tumor burden, hence ignoring disease history. However, if left untreated, tumors grow exponentially, implying that pretreatment changes in tumor size are key to...
Autores principales: | Mercier, Francois, Meneses-Lorente, Georgina, Grimsey, Paul, Phipps, Alex, Michielin, Francesca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259628/ https://www.ncbi.nlm.nih.gov/pubmed/32470048 http://dx.doi.org/10.1371/journal.pone.0233882 |
Ejemplares similares
-
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations
por: Meneses-Lorente, Georgina, et al.
Publicado: (2023) -
Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors
por: Meneses-Lorente, Georgina, et al.
Publicado: (2021) -
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)
por: Meneses-Lorente, Georgina, et al.
Publicado: (2021) -
Strategies for clinical dose optimization of T cell-engaging therapies in oncology
por: Ball, Kathryn, et al.
Publicado: (2023) -
PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse‐Type Tenosynovial Giant Cell Tumor
por: Smart, Kevin, et al.
Publicado: (2020)